sulfasalazine has been researched along with Alopecia in 4 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Alopecia: Absence of hair from areas where it is normally present.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Despite NUDT15 variants showing significant association with thiopurine-induced adverse events (AEs) in Asians, it remains unclear which variants of NUDT15 or whether additional genetic variants should be tested to predict AEs." | 1.48 | NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study. ( Andoh, A; Araki, H; Endo, K; Hanai, H; Hiraoka, S; Hisamatsu, T; Hokari, R; Ikeya, K; Ishiguro, Y; Kakuta, Y; Kawai, Y; Kinouchi, Y; Kobayashi, T; Masamune, A; Matsumoto, T; Miura, M; Mizuno, S; Moroi, R; Motoya, S; Naganuma, M; Nagasaki, M; Naito, T; Nakagawa, S; Nakagawa, T; Nakamura, S; Nakase, H; Nishida, A; Okamoto, D; Onodera, K; Sakuraba, H; Sasaki, M; Shiga, H; Shimosegawa, T; Shinozaki, M; Suzuki, Y; Takagawa, T; Takahara, M; Toyonaga, T; Yanai, S, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kakuta, Y | 1 |
| Kawai, Y | 1 |
| Okamoto, D | 1 |
| Takagawa, T | 1 |
| Ikeya, K | 1 |
| Sakuraba, H | 1 |
| Nishida, A | 1 |
| Nakagawa, S | 1 |
| Miura, M | 1 |
| Toyonaga, T | 1 |
| Onodera, K | 1 |
| Shinozaki, M | 1 |
| Ishiguro, Y | 1 |
| Mizuno, S | 1 |
| Takahara, M | 1 |
| Yanai, S | 1 |
| Hokari, R | 1 |
| Nakagawa, T | 1 |
| Araki, H | 1 |
| Motoya, S | 1 |
| Naito, T | 1 |
| Moroi, R | 1 |
| Shiga, H | 1 |
| Endo, K | 1 |
| Kobayashi, T | 1 |
| Naganuma, M | 1 |
| Hiraoka, S | 1 |
| Matsumoto, T | 1 |
| Nakamura, S | 1 |
| Nakase, H | 1 |
| Hisamatsu, T | 1 |
| Sasaki, M | 1 |
| Hanai, H | 1 |
| Andoh, A | 1 |
| Nagasaki, M | 1 |
| Kinouchi, Y | 1 |
| Shimosegawa, T | 1 |
| Masamune, A | 1 |
| Suzuki, Y | 1 |
| Lian, BS | 1 |
| Busmanis, I | 1 |
| Lee, HY | 1 |
| Codeluppi, PL | 1 |
| Chahin, NJ | 1 |
| Merighi, A | 1 |
| Rigo, G | 1 |
| Manenti, F | 1 |
| Fich, A | 1 |
| Eliakim, R | 1 |
4 other studies available for sulfasalazine and Alopecia
| Article | Year |
|---|---|
NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.
Topics: Alopecia; Antibodies, Monoclonal; Azathioprine; Biomarkers, Pharmacological; Genetic Predisposition | 2018 |
Relapsing Course of Sulfasalazine-Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Complicated by Alopecia Universalis and Vitiligo.
Topics: Alopecia; Antirheumatic Agents; Arthritis, Rheumatoid; Biopsy; Cyclosporine; Dermatologic Agents; Dr | 2018 |
A complication of SASP therapy: hair loss.
Topics: Alopecia; Colitis, Ulcerative; Female; Humans; Middle Aged; Recurrence; Sulfasalazine | 1987 |
Does sulfasalazine induce alopecia?
Topics: Adult; Alopecia; Colitis, Ulcerative; Female; Humans; Pregnancy; Pregnancy Complications; Puerperal | 1988 |